BRCA1 and neoplasm: In a shift towards precision medicine, FidoCure® DNA sequencing revealed mutations in BRCA1 and PTEN within the tumor, indicating that targeted therapies with PARPi olaparib and mTOR inhibitor rapamycin could be beneficial and effective [92].